Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


12 07, 2013

I survived another “triple witching therapy hour!”

Tags: , , , , , , |7 Comments

What the heck is a "triple witching hour?" According to Mark Koba, Senior Business Editor for CNBC, "Witching hours occur when financial contracts—specifically options and futures—end on the third Friday of a month.  Traditionally, all contracts expire in the same hour—thus the name witching hour—usually the last hour of trading." And the end of the

9 04, 2012

The crazy world of “myeloma research speak”

Tags: , , , , , , , , , , , , , |0 Comments

Most of you probably know that I have been working on several new books about multiple myeloma.  My third book, New Myeloma Therapies from a Patient's Perspective, will be published and available by the end of this month.  Researching this book reminded me about how difficult it can be to understand "myeloma research speak."  It

28 02, 2012

New bone strengthening/anti-myeloma antibody begins Phase Two testing

Tags: , , , , , , , |6 Comments

I have been following the progress of one of our patient readers who also lives in the Tampa area. Richard is getting ready to embark on an exciting ride:  He has been accepted into a clinical study which features an experimental monocolonal antibody called BHQ880. The study is designed to learn whether this newly developed

2 05, 2011

Video Explaining How Bisphosphonates Help Strengthen Bones Of Myeloma Patients

Tags: , , , , , , |0 Comments

I flew out to Los Angeles late last fall to interview Dr. James Berenson at the Institute for Myeloma & Bone Cancer Research. Novartis Oncology paid for my time and travel.  The primary purpose of the trip was to produce a video for Novartis about their IV bisphosphonate drug, Zometa.  An independent company, WEGO Health,

1 03, 2011

New Webinar About Bone Health For Multiple Myeloma Survivors Available Online

Tags: , , , , , , |0 Comments

Yesterday I provided you with a link to a site on, where patients and/or caregivers can access video footage of other patients, all discussing how they live with their cancer. Today I would like to share a link to a webinar I conducted late last year with Dr. James Berenson in Los Angeles: Multiple Myeloma

5 12, 2010

Evidence Shows Zometa Features Anti-Myeloma Benefit For Patients. But How About Another Often Used Bisphosphonate, Aredia?

Tags: , , |2 Comments

This article from WebMD speaks for itself:Bone Drug May Help Treat Multiple MyelomaStudy Shows Zometa May Improve Survival for Patients With Multiple MyelomaBy Salynn BoylesWebMD Health NewsReviewed by Laura J. Martin, MD Dec. 3, 2010 -- Adding the intravenous bone drug Zometa to chemotherapy improves survival in patients with the blood cancer multiple myeloma, new

19 11, 2010

FDA Approves New Cancer Bone Drug, Denosumab (Xgeva), For Use In Patients With Solid Tumors – But Not Multiple Myeloma

Tags: , , , , , , , |4 Comments

Hot "off the presses," here is yesterday afternoon's announcement from the FDA as reported by Reuters:FDA OKs Amgen's bone drug in certain cancersNov 18 2010 - By Deena Beasley* Denosumab approved for patients with solid tumors * Not approved for multiple myeloma* Shares rise 1.6 percent LOS ANGELES, Nov 18 (Reuters) - The U.S. Food

30 10, 2010

New Study Confirms Less Is More When Using The Bisphosphonate, Aredia, In Multiple Myeloma Patients

Tags: , , , , , , |0 Comments

Lots of excitement and questions swirling around bisphosphonates lately.  Aredia is the tried and true, less expensive, more conservative option.  Zometa is much stronger than Aredia and requires a far shorter infusion time.  Both drugs can cause osteonecrosis of the jaw (OMJ).  A brand new alternative, Prolia should also be available soon.  There are other

28 10, 2010

Unexpected Tour Of The Institute For Myeloma & Bone Cancer Research: Interview With Dr. James Berenson- Part Three

Tags: , , , , |1 Comment

There is no question stem cell transplants (SCTs) help many patients for a number of years. But the procedure is not without risk—and some patients get very little benefit in the end.As with most things in life, timing is everything! How and when it is best to undergo a SCT is one of the most

24 10, 2010

The Myeloma Beacon Reports Details About FDA’s Bisphosphonate Alert

Tags: , , |0 Comments

There has been a lot of interest and concern about the recent FDA warning about bone strengthening drugs like Fosamax, Actonel, Boniva, Reclast and Boniva.The Myeloma Beacon ran a reassuring article about the warnings for multiple myeloma patients taking the IV bisphosphonates Aredia and Zometa:New FDA Warning About Bisphosphonates Does Not Apply To Multiple Myeloma

24 05, 2010

ASCO News About Bisphosphonates

Tags: , , |0 Comments

There has been a long standing debate among the myeloma community concerning bisphosphonates.  Many myeloma docs now believe Zometa and Aredia provide anti-myeloma benefits, in addition to helping bones recover.  I received the following e-mail Friday from Larry, following release of pre-ASCO research data.  Larry represents a group of multiple myeloma patients who take this research very,

10 09, 2009


Tags: , , |0 Comments

There is a new, soon to be approved bone strengthener called Denusomab. All three physician/speakers at last week's conference seemed excited about this new drug. describes the new drug this way:Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the